YouTube video

Hagen Kennecke, MD, MHA, FRCPC: Benefit of Cabozantinib in Patients with Advanced Neuroendocrine Tumors

Hagen Kennecke, a medical oncologist and professor of medicine at Oregon Health Sciences University, discusses the efficacy of cabozantinib in patients with advanced neuroendocrine tumors, specifically in relation to progression-free survival.

MORE Expert Perspectives in NET

Hagen Kennecke, MD, MHA, FRCPC: Cabozantinib as a Treatment Option Following Progression in NET

Dr. Hagen Kennecke discusses the use of cabozantinib in the treatment of patients with NET who progressed on prior therapies.

Neena Vijayvergia, MD: Importance of Patient Education for Treating Neuroendocrine Tumors

Dr. Vijayvergia emphasizes the importance of patient-physician communication and patient education when treating neuroendocrine tumors.
Facebook Linkedin

©2026 Oncology Matrix. All Rights Reserved.